Everything below concerns preclinical research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
=== Similar species === The false chanterelle (Hygrophoropsis aurantiaca) has a similar appearance and can be confused with the chanterelle. Distinguishing factors are that false chanterelles have true gills, while chanterelles have folds. Additionally, color can help distinguish the two; the true chanterelle is uniform egg-yellow, while the false chanterelle is more orange in hue and graded, with darker center. The true chanterelle's folds are typically more wrinkled or rounded, and randomly forked. Though once thought to be hazardous, it is now known that the false chanterelle is edible but, according to Edible Wild Mushrooms of North America, not especially tasty, and ingesting it may result in mild gastrointestinal distress. The poisonous species in the genus Omphalotus (the jack-o'-lantern mushrooms) have been misidentified as chanterelles, but can usually be distinguished by their well-developed, unforked true gills. Species of Omphalotus are not closely related to chanterelles. Other species in the closely related genera Cantharellus and Craterellus may appear similar to the golden chanterelle. Turbinellus floccosus is sometimes mistaken for a chanterelle due to its orange colour and vein-like hymenium. However, it can be distinguished by its distinctly vase-like form, scaly cap surface, and generally hollow stem.
the exact colour of the spore powder (white/cream/ochre), the taste (mild/bitter/acrid), colour changes in the flesh, the distance from the centre to which the cap skin can be pulled off: (peeling percentage). cap colour (but this is often very variable within one species), reaction of the flesh to ferrous sulphate (FeSO4), formalin, alkalis, and other chemicals, ornamentation of the spores, and other microscopic characteristics, such as the appearance of the cystidia in various mounting reagents. Despite the difficulty in positively identifying collected specimens, the possibility to spot the toxic species by their acrid taste makes some of the mild species, such as R. cyanoxantha and R. vesca, popular edible mushrooms. Russula is mostly free of deadly poisonous species, and mild-tasting ones are all edible.
which is the expression for the strain energy density of a Neo-Hookean solid. Several compressible versions of the Gent model have been designed. One such model has the form (the below strain energy function yields a non zero hydrostatic stress at no deformation, refer for compressible Gent models).
=== Subtypes of soft-tissue sarcoma === Liposarcoma (includes the following varieties: atypical lipomatous tumor/well-differentiated liposarcoma, dedifferentiated liposarcoma, myxoid sarcoma, pleomorphic liposarcoma, and myxoid pleomorphic liposarcoma Atypical lipomatous tumor Dermatofibrosarcoma protuberans (includes pigmented varieties) Dermatofibrosarcoma protuberans, fibrosarcomatous Giant cell fibroblastoma Malignant solitary fibrous tumor Inflammatory myofibroblastic tumor Low-grade myofibroblastic sarcoma Fibrosarcoma (includes adult and sclerosing epithelioid varieties) Myxofibrosarcoma (formerly myxoid malignant fibrous histiocytoma) Low-grade fibromyxoid sarcoma Giant cell tumor of soft tissues Leiomyosarcoma Malignant glomus tumor Rhabdomyosarcoma (includes the following varieties: embryonal, alveolar, pleomorphic, and spindle cell/sclerosing) Hemangioendothelioma (includes the following varieties: retiform, pseudomyogenic, and epithelioid) Angiosarcoma of soft tissue Extraskeletal osteosarcoma Gastrointestinal stromal tumor, malignant (GIST) Malignant peripheral nerve sheath tumor (includes epithelioid variety) Malignant Triton tumor Malignant granular cell tumor Malignant ossifying fibromyxoid tumor Stromal sarcoma not otherwise specified Myoepithelial carcinoma Malignant phosphaturic mesenchymal tumor Skin sarcomas Synovial sarcoma (includes the following varieties: spindle cell, biphasic, and not otherwise specified) Epithelioid sarcoma Alveolar soft part sarcoma Clear cell sarcoma of soft tissue Extraskeletal myxoid chondrosarcoma Extraskeletal Ewing sarcoma Interdigitating dendritic cell sarcoma Desmoplastic small round cell tumor Extrarenal rhabdoid tumor Perivascular epithelioid cell tumor, not otherwise specified Intimal sarcoma Undifferentiated spindle cell sarcoma Undifferentiated pleomorphic sarcoma Undifferentiated round cell sarcoma Undifferentiated epithelioid sarcoma Undifferentiated sarcoma, not otherwise specified.
Sources: en.wikipedia.org
==== Reform policies ==== A broad range of interventionist reforms were introduced by the 1892–1895 Liberal government in areas such as housing, public health, and working conditions. Historian Walter L. Arnstein concludes:
Subclass † Ellesmeroceratoidea Order † Plectronocerida (501 to 490 Ma) Order † Protactinocerida Order † Yanhecerida Order † Ellesmerocerida (500 to 470 Ma) Subclass † Endoceratoidea (485 to 430 Ma) Order † Endocerida (485 to 430 Ma) Order † Intejocerida (485 to 480 Ma) Subclass † Actinoceratoidea Order † Actinocerida (480 to 312 Ma) Subclass Nautiloidea (490.0 Ma- Rec) Order † Basslerocerida (490 to 480 Ma) Order † Tarphycerida (485 to 386 Ma) Order † Lituitida (485 to 480 Ma) Order † Discosorida (482 to 392 Ma) Order † Oncocerida (478.5 to 324 Ma) Order Nautilida (410.5 Ma-Rec) Subclass † Orthoceratoidea (482.5 to 211.5 Ma) Order † Orthocerida (482.5 to 211.5 Ma) Order † Ascocerida (478 to 412 Ma) Order † Dissidocerida (479 to 457.5 Ma) Order † Bajkalocerida Subclass † Bactritoidea (422 to 252 Ma) Subclass † Ammonoidea (410 to 66 Ma) Subclass Coleoidea (410.0 Ma-rec)
== Research directions == Research into diagnosis has aimed to develop new blood tests, including tests that could be used for those who are not currently eating gluten. These tests measure certain immune cells that react to gluten, such as CD4+ T cells and HLA-DQ-gluten tetramers. New technologies have been developed to help people follow a GFD in recent years. Food sensors, such as the Nima sensor, could help people measure the amount of gluten in food to prevent accidental gluten consumption. Testing kits that measure gluten levels in urine and waste may help measure adherence the GFD. Many strategies have been proposed to develop new treatments for coeliac disease. Altering wheat to be safer for those with coeliac disease has been explored using methods such as genetic wheat manipulation and using a chemical process (transamidation) that changes gluten proteins so they no longer trigger an immune reaction. Medications and techniques such as chitosan and AGY gluten sequestering aim to prevent gluten from interacting with the immune system. Glutenases are enzymes taken with food designed to help break down and neutralise gluten in the intestines. Glutenases being studied as of 2022 include latiglutenase–ALV003, Aspergillus niger prolyl endoprotease, Kuma030–TAK-062, and endoproptease-40. Larazotide acetate is a peptide that helps tighten the junctions between intestinal cells, reducing intestinal permeability. It helps decrease reactions to gluten by preventing gluten fragments from passing through the gut lining and triggering the immune system.
Sources: en.wikipedia.org
The Source 2006 branch was the term used for Valve's games using technology that culminated with the release of Half-Life 2: Episode One. HDR rendering and color correction were first implemented in 2005 using Day of Defeat: Source, which required the engine's shaders to be rewritten. The former, along with developer commentary tracks, were showcased in Half-Life 2: Lost Coast. Episode One introduced Phong shading and other smaller features. Image-based rendering technology had been in development for Half-Life 2, but was cut from the engine before its release and mentioned again by Gabe Newell in 2006 as a piece of technology he would like to add to Source to implement support for much larger scenes that are impossible with strictly polygonal objects.
=== Aminopeptidase === The aminopeptidase test analyzes bacteria for the production of the enzyme L-alanine-aminopeptidase, an enzyme found in many gram-negative bacteria. Adding L-Alanine-4-nitroanilide hydrochloride to a bacterial culture works as an indicator, changing to a yellow color in the presence of L-alanine-aminopeptidase.
The samples were found to be "masses of virtually pure collagen" and not to have the "biochemical characteristics of invertebrate collagen, nor the collagen fiber arrangement of octopus mantle." The results suggest the samples are "the remains of the skin of an enormous warm-blooded vertebrate." The authors conclude that "there is no evidence to support the existence of Octopus giganteus" and concur with Verrill (1897) and Lucas (1897) that the St. Augustine carcass was "the remains of a whale, likely the entire skin [blubber layer] . . . nothing more or less."
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.